Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
EIF2 is a translation initiation factor that catalyzes the first regulated step of protein synthesis, promoting the binding of the initiator tRNA to 40s ribosomal subunits. eIF2 is composed of 3 non identical subunits, alpha, beta and gamma. Binding occurs as a ternary complex of methionyl-tRNA, eIF2 and GTP. The rate of complex formation is modulated by the phosphorylation state of eIF2alpha. Phosphorylation of eIF2alpha has been shown to occur in response to heat shock and hypoxic stress.
Western blot of extracts (35 ug) from 9 different cell lines by using anti-EIF2S1 monoclonal antibody.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY EIF2S1 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-EIF2S1.
Flow cytometry of Jurkat cells, using anti-EIF2S1 antibody, (Red), compared to a nonspecific negative control antibody, (Blue).
HEK293T cells transfected with either overexpress plasmid (Red) or empty vector control plasmid (Blue) were immunostained by anti-EIF2S1 antibody, and then analyzed by flow cytometry.